October 2024 in “International Journal of Pharmaceutical Sciences Review and Research” A 5% minoxidil spray could effectively treat male baldness with fewer side effects and better patient comfort.
July 2024 in “ADMET & DMPK” Surface-modified nanostructured lipid carriers can improve hair growth treatments.
The new gel for hair loss is safe, effective, and reduces side effects.
May 2024 in “EAS Journal of Pharmacy and Pharmacology” Pomegranate peel compounds may help treat hair loss.
April 2024 in “Frontiers in pharmacology” Cynoglossum amabile has medicinal potential but poses safety concerns due to liver toxicity.
March 2024 in “Bioimpacts” 400 nm particles penetrate hair follicles best, but mouse models aren't fully reliable for human studies.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
Pomegranate is beneficial in various medical fields.
June 2023 in “Journal of chemical metrology” A new method found unlisted drugs in two popular hair serums, posing a health risk.
December 2022 in “Sudan Journal of Medical Sciences” Vaccination is the most effective way to reduce COVID-19 transmission.
June 2022 in “Organic communications” Natural compounds, especially Withaferin-A, may help treat post-COVID-19 complications, but some may have side effects.
October 2021 in “Research Society and Development” Herbal medicines can reduce the effectiveness of birth control pills.
October 2020 in “Veterinary Dermatology” New treatments and diagnostic methods for various animal skin conditions showed promising results.
November 2019 in “Harper's Textbook of Pediatric Dermatology” The document is a detailed medical reference on skin and genetic disorders.
January 2019 in “ARC journal of pharmaceutical sciences” Acne can be managed with various treatments and requires psychological support due to its emotional impact.
Accurate diagnosis and timely, tailored treatments improve outcomes in obstetrics and gynecology.
December 2013 in “Biomedical and biopharmaceutical research” Nanotechnology shows promise for better drug delivery and cancer treatment.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
February 2013 in “Journal of The American Academy of Dermatology” There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
September 2009 in “Pediatric Dermatology” UVB is good for a skin condition in Asian kids, a lotion works for head lice, a drug helps with a skin blistering disorder, a foam reduces itchiness in skin inflammation, birthmarks can be more widespread, and criteria for a neurocutaneous disorder were agreed upon.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
April 2018 in “Journal of Chromatographic Science” Finasteride's stability and safety confirmed through precise analytical methods.
July 2021 in “Research Square (Research Square)” Semecarpus anacardium leaf extract fights breast cancer and extends survival in mice.
855 citations
,
June 2009 in “The Journal of Clinical Endocrinology & Metabolism” The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.
310 citations
,
November 2011 in “Environment International” Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.
282 citations
,
October 2006 in “The Journal of Clinical Endocrinology and Metabolism” The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.
271 citations
,
December 2005 in “New England journal of medicine/The New England journal of medicine” The document likely offers guidance on treating a woman's excessive hair growth, considering her symptoms and obesity.
251 citations
,
October 2014 in “The Journal of Clinical Endocrinology & Metabolism” The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.